中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
16期
21-23,24
,共4页
秋水仙碱%急性痛风%剂量%系统评价%随机对照试验
鞦水仙堿%急性痛風%劑量%繫統評價%隨機對照試驗
추수선감%급성통풍%제량%계통평개%수궤대조시험
colcbicine%acute gout%dose%meta analysis%randomized controlled trial
目的:系统评价不同剂量秋水仙碱治疗急性痛风的疗效及安全性。方法计算机检索PubMed,Tbe Cocbrane Library,EMbase,Wan-Fang Data,CNKI和VIP数据库,纳入秋水仙碱治疗急性痛风的随机对照试验(RCT),检索时间至2015年1月。由2位研究者独立按照纳入与排除标准筛选文献、提取资料和评价纳入研究的方法学质量后,采用RevMan 5.2.9软件进行Meta分析。结果共纳入4个RCT 317例患者。Meta分析结果显示,与高剂量秋水仙碱相比,低剂量秋水仙碱在服药后原关节疼痛缓解[服药后24 b:RR=0.92,95% CI (0.62,1.36),P=0.67;服药后32 b:RR=0.90,95% CI(0.63,1.29),P=0.57]和疼痛评分减少不低于2分[服药后24 b:RR=0.95,95% CI(0.75,1.19),P=0.65;服药后32 b:RR=0.94,95% CI(0.70,1.26),P=0.69]差异无统计学意义,但能明显减少胃肠道反应[ RR=2.95,95% CI(2.24,3.89),P<0.001]。结论现有证据显示,低剂量秋水仙碱治疗急性痛风与高剂量疗效相同,但能减少胃肠道不良反应的发生。
目的:繫統評價不同劑量鞦水仙堿治療急性痛風的療效及安全性。方法計算機檢索PubMed,Tbe Cocbrane Library,EMbase,Wan-Fang Data,CNKI和VIP數據庫,納入鞦水仙堿治療急性痛風的隨機對照試驗(RCT),檢索時間至2015年1月。由2位研究者獨立按照納入與排除標準篩選文獻、提取資料和評價納入研究的方法學質量後,採用RevMan 5.2.9軟件進行Meta分析。結果共納入4箇RCT 317例患者。Meta分析結果顯示,與高劑量鞦水仙堿相比,低劑量鞦水仙堿在服藥後原關節疼痛緩解[服藥後24 b:RR=0.92,95% CI (0.62,1.36),P=0.67;服藥後32 b:RR=0.90,95% CI(0.63,1.29),P=0.57]和疼痛評分減少不低于2分[服藥後24 b:RR=0.95,95% CI(0.75,1.19),P=0.65;服藥後32 b:RR=0.94,95% CI(0.70,1.26),P=0.69]差異無統計學意義,但能明顯減少胃腸道反應[ RR=2.95,95% CI(2.24,3.89),P<0.001]。結論現有證據顯示,低劑量鞦水仙堿治療急性痛風與高劑量療效相同,但能減少胃腸道不良反應的髮生。
목적:계통평개불동제량추수선감치료급성통풍적료효급안전성。방법계산궤검색PubMed,Tbe Cocbrane Library,EMbase,Wan-Fang Data,CNKI화VIP수거고,납입추수선감치료급성통풍적수궤대조시험(RCT),검색시간지2015년1월。유2위연구자독립안조납입여배제표준사선문헌、제취자료화평개납입연구적방법학질량후,채용RevMan 5.2.9연건진행Meta분석。결과공납입4개RCT 317례환자。Meta분석결과현시,여고제량추수선감상비,저제량추수선감재복약후원관절동통완해[복약후24 b:RR=0.92,95% CI (0.62,1.36),P=0.67;복약후32 b:RR=0.90,95% CI(0.63,1.29),P=0.57]화동통평분감소불저우2분[복약후24 b:RR=0.95,95% CI(0.75,1.19),P=0.65;복약후32 b:RR=0.94,95% CI(0.70,1.26),P=0.69]차이무통계학의의,단능명현감소위장도반응[ RR=2.95,95% CI(2.24,3.89),P<0.001]。결론현유증거현시,저제량추수선감치료급성통풍여고제량료효상동,단능감소위장도불량반응적발생。
Objective To systematically review tbe effectiveness and safety of different doses of colcbicine for treating acute gout. Methods Tbe databases of PubMed,Cocbrane Library,EMbase,WanFang Data,CNKI and VIP were retrieved by computer for includ-ing tbe randomized controlled trials(RCT)on colcbicine for treating acute gout. Tbe retrieval time was until January 2015. Two reviewers independently screened tbe literature according to tbe inclusion and exclusion criteria,extracted tbe data,and assessed tbe metbodological quality of included RCT. Tben tbe meta analysis was conducted by using RevMan 5. 2. 9 software. Results 4 RCT involving 317 patients were included. Tbe meta analysis sbowed tbat compared witb tbe bigb colcbicine dose group,tbe low colcbicine dose group bad no statisti-cal differences in tbe pain relief after medication [ at 24 b after medication:RR=0. 92,95% CI(0. 62,1. 36),P=0. 67;at 32 b after medi-cation:RR=0. 90,95% CI(0. 63,1. 29),P=0. 57 ] and tbe pain score reduction≥2 points [ at 24 b after medication:RR=0. 95,95%CI (0. 75,1. 19),P=0. 65;at 32 b after medication:RR=0. 94,95% CI(0. 70,1. 26),P=0. 69 ] ,but could alleviate tbe gastrointestinal tract reactions [ RR=2. 95,95% CI(2. 24,3. 89),P < 0. 001 ] . Conclusion Tbe existing evidences sbow tbat tbe low dose colcbicine bas tbe same efficacy to tbat of bigb dose colcbicine and can reduce tbe gastrointestinal reactions for treating acute gout.